Recent updates on targeting the molecular mediators of NAFLD.
Jia WangLei WangXiao-Jing ZhangPeng ZhangJingjing CaiZhi-Gang SheHong Liang LiPublished in: Journal of molecular medicine (Berlin, Germany) (2023)
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common disease worldwide in an era of rapid economic growth. NAFLD is a multifactorial disease, involving multiple genetic, metabolic, and environmental factors, and is closely associated with metabolic syndrome, obesity, and cardiovascular disease. NAFLD can be classified into nonalcoholic fatty liver disease (NAFL) and nonalcoholic steatohepatitis (NASH), which can both progress to cirrhosis and even hepatocellular carcinoma (HCC). Due to the enormous burden of NAFLD and its complications, no FDA-approved drugs for the treatment of NAFLD are on the market, and therapeutic targets and drug therapies are being actively investigated. In view of the various pathological mechanisms of NAFLD, numbers of preclinical studies and clinical trials have made rapid progress. This review mainly summarizes the most recently characterized mechanisms and therapeutic targets in each mechanism of NAFLD, focusing on the mechanism and application potential.
Keyphrases
- metabolic syndrome
- cardiovascular disease
- clinical trial
- type diabetes
- insulin resistance
- stem cells
- emergency department
- body mass index
- adipose tissue
- weight loss
- health insurance
- gene expression
- risk assessment
- mass spectrometry
- bone marrow
- dna methylation
- high resolution
- genome wide
- uric acid
- skeletal muscle
- copy number
- loop mediated isothermal amplification